Arkolith/Insider Trading/LYEL/Form 4

Newton Charles W.

Chief Financial OfficerLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Aug 13, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3K
Net Open-Market Flow
-$3K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 12, 2025Sell(S)136$10.34$1K9K
Aug 11, 2025Sell(S)131$10.53$1K9K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-021691) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML